A citation-based method for searching scientific literature

Clifford M Csizmar, Antoine N Saliba, Elizabeth M Swisher, Scott H Kaufmann. Cancers (Basel) 2021
Times Cited: 5







List of co-cited articles
16 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B Baylin, Daniela Matei, Harikrishna Nakshatri,[...]. Clin Cancer Res 2018
67
40

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Antonella Padella, Andrea Ghelli Luserna Di Rorà, Giovanni Marconi, Martina Ghetti, Giovanni Martinelli, Giorgia Simonetti. J Hematol Oncol 2022
5
40

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Nidal E Muvarak, Khadiza Chowdhury, Limin Xia, Carine Robert, Eun Yong Choi, Yi Cai, Marina Bellani, Ying Zou, Zeba N Singh, Vu H Duong,[...]. Cancer Cell 2016
113
40

Therapeutic Targeting of DNA Damage Response in Cancer.
Wonyoung Choi, Eun Sook Lee. Int J Mol Sci 2022
11
40

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
40

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
40


Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria I Harrell, Giada V Zapparoli, Alison Hadley, Robert Holian, Emma Boehm,[...]. Nat Commun 2018
125
40

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
40


PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.
Benu Brata Das, Shar-yin N Huang, Junko Murai, Ishita Rehman, Jean-Christophe Amé, Souvik Sengupta, Subhendu K Das, Papiya Majumdar, Hongliang Zhang, Denis Biard,[...]. Nucleic Acids Res 2014
135
40

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan, Daniel Suzman, Erik Bloomquist, Shenghui Tang, Yutao Gong, Rajeshwari Sridhara,[...]. Oncologist 2021
44
40

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
410
40

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
40

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
651
40

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
759
40

5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells.
Christoph Oing, Izudin Verem, Wael Y Mansour, Carsten Bokemeyer, Sergey Dyshlovoy, Friedemann Honecker. Int J Mol Sci 2018
22
20

Eukaryotic cytosine methyltransferases.
Mary Grace Goll, Timothy H Bestor. Annu Rev Biochem 2005
20

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Sha Jin, Dan Cojocari, Julie J Purkal, Relja Popovic, Nari N Talaty, Yu Xiao, Larry R Solomon, Erwin R Boghaert, Joel D Leverson, Darren C Phillips. Clin Cancer Res 2020
54
20

Dynamics of DNA demethylation.
Tal Nawy. Nat Methods 2013
5
20

The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
Tatiana Kamaletdinova, Zahra Fanaei-Kahrani, Zhao-Qi Wang. Cells 2019
51
20

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
Louise J Barber, Shahneen Sandhu, Lina Chen, James Campbell, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Daniel Nava Rodrigues, Jorge S Reis Filho, Victor Moreno,[...]. J Pathol 2013
230
20

DNA Methylation Reprogramming during Mammalian Development.
Yang Zeng, Taiping Chen. Genes (Basel) 2019
127
20

Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Verona Buocikova, Eleonora Marta Longhin, Eleftherios Pilalis, Chara Mastrokalou, Svetlana Miklikova, Marina Cihova, Alexandra Poturnayova, Katarina Mackova, Andrea Babelova, Lenka Trnkova,[...]. Biomed Pharmacother 2022
7
20

The transcriptional landscape and mutational profile of lung adenocarcinoma.
Jeong-Sun Seo, Young Seok Ju, Won-Chul Lee, Jong-Yeon Shin, June Koo Lee, Thomas Bleazard, Junho Lee, Yoo Jin Jung, Jung-Oh Kim, Jung-Young Shin,[...]. Genome Res 2012
413
20

Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements.
Gangning Liang, Matilda F Chan, Yoshitaka Tomigahara, Yvonne C Tsai, Felicidad A Gonzales, En Li, Peter W Laird, Peter A Jones. Mol Cell Biol 2002
403
20

Kinase-mediated changes in nucleosome conformation trigger chromatin decondensation via poly(ADP-ribosyl)ation.
Colin J Thomas, Elena Kotova, Mark Andrake, Jared Adolf-Bryfogle, Robert Glaser, Catherine Regnard, Alexei V Tulin. Mol Cell 2014
30
20

Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer.
Huanhuan Sha, Yujie Gan, Renrui Zou, Jianzhong Wu, Jifeng Feng. Front Oncol 2021
2
50


Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.
Neeraj Agarwal, Arun Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy,[...]. Future Oncol 2022
4
25


DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load.
Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Manel Esteller, Se-Hoon Lee, Jung Kyoon Choi. Nat Commun 2019
148
20

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer.
Nair Lopes, Mariana Brütt Pacheco, Diana Soares-Fernandes, Margareta P Correia, Vânia Camilo, Rui Henrique, Carmen Jerónimo. Biomedicines 2021
1
100

TET family dioxygenases and DNA demethylation in stem cells and cancers.
Jungeun An, Anjana Rao, Myunggon Ko. Exp Mol Med 2017
88
20

PARP1 orchestrates epigenetic events setting up chromatin domains.
Fabio Ciccarone, Michele Zampieri, Paola Caiafa. Semin Cell Dev Biol 2017
64
20

Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs.
Francesco Neri, Anna Krepelova, Danny Incarnato, Mara Maldotti, Caterina Parlato, Federico Galvagni, Filomena Matarese, Hendrik G Stunnenberg, Salvatore Oliviero. Cell 2013
120
20

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
J G Herman, F Latif, Y Weng, M I Lerman, B Zbar, S Liu, D Samid, D S Duan, J R Gnarra, W M Linehan. Proc Natl Acad Sci U S A 1994
20

Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.
Peter Makhov, Robert G Uzzo, Alexei V Tulin, Vladimir M Kolenko. Urol Oncol 2021
5
20


Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression.
Jun Gao, Lihua Wang, Jinkang Xu, Jianming Zheng, Xiaohua Man, Hongyu Wu, Jin Jin, Kaixuan Wang, Huasheng Xiao, Shude Li,[...]. J Exp Clin Cancer Res 2013
49
20


Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions.
M Malanga, J M Pleschke, H E Kleczkowska, F R Althaus. J Biol Chem 1998
187
20


5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes.
W M Rideout, G A Coetzee, A F Olumi, P A Jones. Science 1990
566
20

TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair.
Yimei Feng, Xiaoping Li, Kaniel Cassady, Zhongmin Zou, Xi Zhang. Front Oncol 2019
53
20

Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.
Bodo Brueckner, Maria Rius, Maria Rivera Markelova, Iduna Fichtner, Petter-Arnt Hals, Marit Liland Sandvold, Frank Lyko. Mol Cancer Ther 2010
60
20


Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.
Mei Han, Lina Jia, Wencai Lv, Lihui Wang, Wei Cui. Front Oncol 2019
38
20

Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy.
Yaroslava Karpova, Danping Guo, Peter Makhov, Adam M Haines, Dmitriy A Markov, Vladimir Kolenko, Alexei V Tulin. Cancers (Basel) 2021
6
20

Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.
Anna Dolnik, Julia C Engelmann, Maren Scharfenberger-Schmeer, Julian Mauch, Sabine Kelkenberg-Schade, Berit Haldemann, Tamara Fries, Jan Krönke, Michael W M Kühn, Peter Paschka,[...]. Blood 2012
110
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.